JAM3 and neoplasm: By using the LLC1 tumor model in the dorsal skin-fold chamber, we looked at the recruitment of e-EPCs to tumor angiogenesis and, by interfering with JAM-C function via H33 monoclonal antibody, we observed effects on multiple steps, including firm adhesion, incorporation and sprouting.